Evidence map›Paper›PMID 40503915›Full record

ArticleJournal of virology2025

Convergent evolution in nucleocapsid facilitated SARS-CoV-2 adaptation for human infection.

Kumari G Lokugamage, Yiyang Zhou, R Elias Alvarado, Jessica A Plante, Yani Ahearn, Jennifer Chen, Leah Estes, William Meyers, Jakob Nilsson, Andrew L Routh and 3 more

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kumari G LokugamageDepartment of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA.
Yiyang ZhouDepartment of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA.
R Elias AlvaradoDepartment of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA.
Jessica A PlanteWorld Reference Center of Emerging Viruses and Arboviruses, The University of Texas Medical Branch, Galveston, Texas, USA.
Yani AhearnDepartment of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA.
Jennifer ChenDepartment of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA.
Leah EstesDepartment of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA.
William MeyersDepartment of Pathology, The University of Texas Medical Branch, Galveston, Texas, USA.
Jakob NilssonNovo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Andrew L RouthDepartment of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, Texas, USA.ORCID 0000-0002-2874-5990
David H WalkerDepartment of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, Texas, USA.
Vineet D MenacheryDepartment of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA.ORCID 0000-0001-8803-7606
Bryan A JohnsonDepartment of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA.ORCID 0000-0002-8999-1255

Funding

Identifying host and viral correlates for coronavirus pathogenesisR01AI153602 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI JOHNSON, BRYAN A · 2020 to 2023
$2.0M
The Host Genetics of Age-Dependent SusceptibilityR21AI145400 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MENACHERY, VINEET D · 2020 to 2021
$451k
Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious DiseaseInstitute of Human Infections and Immunity University of Texas Medical Branch NoneNational Institute of Allergy and Infectious Diseases R01-AI153602,R21-AI145400NIAID NIH HHS R01 AI153602NIAID NIH HHS R21 AI145400University of Texas System STARs Award
6 · The paper itself

Abstract

During the early stages of the COVID-19 pandemic, several SARS-CoV-2 variants of concern (VOCs) independently acquired mutations in the highly variable 203-205 amino acid region of the nucleocapsid (N) protein including R203K + G204R (found in the Alpha, Gamma, and Omicron variants), R203M (in Delta), and T205I (in Beta). In previous research, we demonstrated that the R203K + G204R mutation significantly enhances SARS-CoV-2 N phosphorylation, which subsequently increases viral fitness and pathogenesis. In this study, we investigated the effects of the R203M and T205I mutations on SARS-CoV-2 infection. Using reverse genetics, we introduced these mutations into the early pandemic Washington-1 (WA-1) strain and observed that both the R203M and T205I mutants enhanced replication and viral fitness. However, unlike the R203K + G204R mutant, the R203M and T205I mutants caused only moderate changes in lung pathology. Notably, each mutation-R203K + G204R, R203M, and T205I-induced distinct patterns of N phosphorylation, which likely contribute to the observed phenotypic differences between the mutants. Interestingly, when bat cells expressing human ACE2 were infected with these mutants, we observed a reduction, rather than an enhancement, in both SARS-CoV-2 replication and N phosphorylation. Collectively, our findings suggest that the R203K + G204R, R203M, and T205I mutations are a result of convergent evolution and reflect how SARS-CoV-2 has adapted for human infection.IMPORTANCEAfter its emergence, SARS-CoV-2 rapidly adapted to human infection, acquiring numerous mutations across its genome. Many of these mutations remain uncharacterized. This study examines a mutational hotspot among SARS-CoV-2 variants: residues 203-205 of the nucleocapsid (N) protein. We demonstrate that three unique mutations identified in this region among variants of concern enhance infection in human cells and animal models while eliciting distinct patterns of N protein phosphorylation. Intriguingly, these same mutations reduce both N protein phosphorylation and viral replication in bat cells. These findings suggest that each mutation represents independent adaptation by variants of concern for human infection. Importantly, this study underscores the critical role of these mutations in facilitating the expansion of SARS-CoV-2 into human populations and highlights the potential for similar mutations to drive future zoonotic coronavirus outbreaks.

Indexed as

Coronavirus Nucleocapsid ProteinsCOVID-19NucleocapsidPhosphoproteinsSARS-CoV-2Angiotensin-Converting Enzyme 2AnimalsChiropteraChlorocebus aethiopsEvolution, MolecularHumansMutationPhosphorylationVero CellsVirus ReplicationACE2 protein, humanAngiotensin-Converting Enzyme 2Coronavirus Nucleocapsid Proteinsnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsCOVID-19nucleocapsidSARS-CoV-2variants of concern

Identifiers

PMID40503915
PMCPMC12282136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.